

01-37-00

A

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (4/98)
 Approved for use through 09/30/2000. OMB 0651-0032
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. HS 102 *cup 2*
 First Inventor or Application Identifier Gary A. Bannon
 Title METHODS AND REAGENTS FOR DECREASING CLINICAL
 REACTION TO ALLERGY
 Express Mail Label No. EL 273 005 083 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
 Box Patent Application
 Washington, DC 20231

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
 (Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages
 (preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets
 4. Oath or Declaration [Total Pages
 a. ☒ Unexecuted
 b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
 (for continuation/divisional with Box 16 completed)
 i. ☐ DELETION OF INVENTOR(S)
 Signed statement attached deleting
 inventor(s) named in the prior application,
 see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

5. ☐ Microfiche Computer Program (Appendix)
 6. Nucleotide and/or Amino Acid Sequence Submission
 (if applicable, all necessary)
 a. ☐ Computer Readable Copy
 b. ☐ Paper Copy (identical to computer copy)
 c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
 8. ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of
 (when there is an assignee) Attorney
 9. ☐ English Translation Document (if applicable)
 10. ☐ Information Disclosure ☐ Copies of IDS
 Statement (IDS)/PTO-1449 Citations
 11. ☐ Preliminary Amendment
 12. ☒ Return Receipt Postcard (MPEP 503)
 (Should be specifically itemized)
 13. ☐ * Small Entity ☐ Statement filed in prior application,
 Statement(s) Status still proper and desired
 (PTO/SB/09-12)
 14. ☐ Certified Copy of Priority Document(s)
 (if foreign priority is claimed)
 15. ☒ Other: Check for \$345.00

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY
 FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT
 IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied
 under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by
 reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name	Patreia L. Pabst				
	A small Golden & Gregory, LLP				
Address	2800 One Atlantic Center				
	1201 West Peachtree Street				
City	Atlanta	State	GA	Zip Code	30309-3450
Country	United States	Telephone	(404) 873-8794	Fax	(404) 873-8795

Name (Print/Type)	Patreia L. Pabst	Registration No. (Attorney/Agent)	31,284
Signature	<i>Patreia L. Pabst</i>	Date	January 27, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any
 comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office,
 Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,
 Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin

Serial No.: Express Mail Label No.: EL 273 005 083 US

Filed: January 28, 2000 Date of Deposit January 28, 2000

For: "METHODS AND REAGENTS FOR DECREASING CLINICAL REACTIONS TO ALLERGY"

Assistant Commissioner
for Patents
Washington, D.C. 20231

**EXPRESS MAIL TRANSMITTAL LETTER
FOR PATENT APPLICATION AND CERTIFICATE OF MAILING**

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin enclose for filing the attached patent application entitled "METHODS AND REAGENTS FOR DECREASING CLINICAL REACTIONS TO ALLERGY", which claims priority under 35 U.S.C. § 119 to U.S. PCT/US99/02031, and is a continuation-in-part under 35 U.S.C. § 120 to U.S. Serial No. 09/141,220 filed August 27, 1998, U.S. Serial No. 09/240,557 filed January 29, 1999, U.S. Serial No. 09/241,101 filed January 29, 1999, U.S. Serial No. 09/248,673 filed February 11, 1999, which claim priority to U.S.S.N. 60/073,283 filed January 29, 1998, U.S.S.N. 60/074,590 filed February 13, 1998, and U.S.S. N. 60/074,624 filed February 13, 1998, and U.S.

Serial No. 09/248,674 filed February 11, 1999, and claims priority to U.S.S.N. 60/122,566 filed March 2, 1999. The application includes 1 page of Abstract, 32 pages of specification, 5 pages of claims, and 3 sheets of informal drawings. An executed Declaration, Assignment and A Verified Statement Claiming Small Entity Status will be submitted shortly. A check in the amount of \$345.00 to cover a portion of the filing fee is enclosed.

The Commissioner is hereby authorized to charge our deposit order account no. 01-2507 in the amount of \$1023.00, which represents the difference between the filing fee for a large entity and small entity, and any other fees as appropriate.


This application is being filed on January 28, 2000, by mailing the application to the Assistant Commissioner for Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10. The Express Mail label number appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

"Methods and Reagents for Decreasing Clinical Reaction to Allergy"
Filed: January 28, 2000
Express Mail Transmittal Letter for
Patent Application and Certificate of Mailing
Express Mail Label No. EL 273 005 083 US

The Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment to Deposit Order Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter. All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq.
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: January 28, 2000


ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 Telefax

"Methods and Reagents for Decreasing Clinical Reaction to Allergy"
Filed: January 28, 2000
Express Mail Transmittal Letter for
Patent Application and Certificate of Mailing
Express Mail Label No. EL 273 005 083 US

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this Express Mail Transmittal Letter for Patent Application and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, January 28, 2000, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, mailing label number EL 273 005 083 US, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: January 28, 2000



Patrea L. Pabst

008210" 916046460

METHODS AND REAGENTS FOR DECREASING CLINICAL REACTION TO ALLERGY

Background of the Invention

The United States government has rights in this invention by virtue of grants from the National Institute of Health RO1-AI33596.

This application claims priority under 35 U.S.C. §119 to PCT/US99/02031, and is a continuation-in-part under 35 U.S.C. §120 to U.S. Serial No. 09/141,220 filed August 27, 1998, U.S. Serial No. 09/240,557 filed January 29, 1999, U.S. Serial No. 09/241,101 filed January 29, 1999, U.S. Serial No. 09/248,673 filed February 11, 1999, which claim priority to U.S.S.N. 60/073,283 filed January 29, 1998, U.S.S.N. 60/074,590 filed February 13, 1998, and U.S.S.N. 60/074,624 filed February 13, 1998, and U.S. Serial No. 09/248,674 filed February 11, 1999, and claims priority to U.S.S.N. 60/122,566 filed March 2, 1999.

Allergic disease is a common health problem affecting humans and companion animals (mainly dogs and cats) alike. Allergies exist to foods, molds, grasses, trees, insects, pets, fleas, ticks and other substances present in the environment. It is estimated that up to 8% of young children and 2% of adults have allergic reactions just to foods alone. Some allergic reactions (especially those to foods and insects) can be so severe as to be life threatening. Problems in animals tend to be less severe, but very common. For example, many dogs and cats have allergies to flea saliva proteins, grasses, and other common substances present in the environment.

Allergy is manifested by the release of histamines and other mediators of inflammation by mast cells which are triggered into action when IgE antibodies bound to their receptors on the mast cell surface are cross linked by antigen. Other than avoidance, and drugs (e.g. antihistamines, decongestants, and steroids) that only treat symptoms and can have unfortunate side effects and often only provide temporary relief, the only currently medically accepted

treatment for allergies is immunotherapy. Immunotherapy involves the repeated injection of allergen extracts, over a period of years, to desensitize a patient to the allergen. Unfortunately, traditional immunotherapy is time consuming, usually involving years of treatment, and often fails to achieve its goal of desensitizing the patient to the allergen. Furthermore, it is not the recommended treatment for food allergies, such as peanut allergies, due to the risk of anaphylaxis.

Noon (Noon, *Lancet* 1911; 1:1572-73) first introduced allergen injection immunotherapy in 1911, a practice based primarily on empiricism with non-standardized extracts of variable quality. More recently the introduction of standardized extracts has made it possible to increase the efficacy of immunotherapy, and double-blind placebo-controlled trials have demonstrated the efficacy of this form of therapy in allergic rhinitis, asthma and bee-sting hypersensitivity (BSAC Working Party, *Clin. Exp. Allergy* 1993; 23:1-44). However, increased risk of anaphylactic reactions has accompanied this increased efficacy. For example, initial trials of immunotherapy to food allergens has demonstrated an unacceptable safety:efficacy ratio (Oppenheimer et al. *J Allergy Clin. Immun.* 1992; 90:256-62; Sampson, *J. Allergy Clin. Immun.* 1992; 90:151-52; Nelson et al. *J. Allergy Clin. Immun.* 1996; 99:744-751). Results like these have prompted investigators to seek alternative forms of immunotherapy as well as to seek other forms of treatment.

Initial trials with allergen-non-specific anti-IgE antibodies to deplete the patient of allergen-specific IgE antibodies have shown early promise (Boulet, et al. 1997; 155:1835-1840; Fahy, et al. *American J Respir. Crit. Care Med.* 1997; 155:1828-1834; Demoly P. and Bousquet J. *American J Resp. Crit. Care Med.* 1997; 155:1825-1827). On the other hand, trials utilizing immunogenic peptides (representing T cell epitopes) have been disappointing (Norman, et al. *J. Aller. Clin. Immunol.* 1997; 99:S127). Another form of allergen-specific immunotherapy which utilizes injection of plasmid DNA (Raz et al. *Proc. Nat. Acad. Sci. USA* 1994; 91:9519-9523; Hz et al. *Int. Immunol.* 1996; 8:1405-1411)

[illegible][illegible][illegible][illegible][illegible][illegible][illegible]

using known techniques, such as by binding with antibodies in pooled sera obtained from individuals known to be immunoreactive with the allergen to be modified. Proteins that are modified to alter IgE binding are screened for binding with IgG and/or activation of T cells.

Peanut allergens (Ara h 1, Ara h 2, and Ara h 3) have been used in the examples to demonstrate alteration of IgE binding sites while retaining binding to IgG and activation of T cells. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding were determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

Standard techniques such as a skin test for wheal and flare formation can be used to assess decreased allergenicity of modified proteins, created as described in the examples. The modified allergens can also be tested for binding to IgG and proliferation of T cells, and modified allergens selected for optimal stimulation of T cells and binding IgG.

The immunotherapeutics can be delivered by standard techniques, using injection, by aerosol, sublingually, topically (including to a mucosal surface), and by gene therapy (for example, by injection of the gene encoding the immunotherapeutic into muscle or skin where it is transiently expressed for a time sufficient to induce tolerance).

This method and the criteria for identifying and altering allergens can be used to design useful proteins (including nucleotide molecules encoding the proteins) for use in immunotherapy, to make a vaccine and to genetically engineer organisms such as plants and animals which then produce proteins with less likelihood of eliciting an IgE response. Techniques for engineering plants and animals are well known. Based on the information obtained using the method described in the examples, one can engineer plants or animals to cause either site specific mutations in the gene encoding the protein(s) of interest, or to

knock out the gene and then insert the gene encoding the modified protein.

Brief Description of the Drawings

Figure 1 shows an example of how IgE binding epitopes were mapped to a specific amino acid sequence on the Ara h 1 allergen.

Figure 2 shows how IgE binding epitopes were mapped to a specific amino acid sequence on the Ara h 2 allergen.

Figure 3 shows how IgE binding epitopes were mapped to a specific amino acid sequence on the Ara h 3 allergen.

Figure 4 is a graph of amino acids divided into hydrophobic, polar or charged properties, showing that hydrophobic amino acids are more critical to IgE binding. The type of each amino acid within the Ara h 1 epitopes was assessed relative to its importance to IgE binding. The closed boxes represent the total number of a particular type of amino acid residue found in all of the Ara h 1 epitopes, whereas the open boxes represent the number of that type of residue which, when replaced, was found to result in the loss of IgE binding.

Figure 5 is a graph of the %IgE binding relative to wild type Ara h2 of modified Ara h 2 allergens.

Figure 6 shows the results of T-cell proliferation assays using the native and recombinant wild-type and modified Ara h 2 protein, compared to crude peanut as a control.

Detailed Description of the Invention

Definitions

The following definitions are used herein.

An antigen is a molecule that elicits production of antibody (a humoral response) or an antigen-specific reaction with T cells (a cellular response).

An allergen is a subset of antigens which elicits IgE production in addition to other isotypes of antibodies.

An allergic reaction is one that is IgE mediated with clinical symptoms primarily involving the cutaneous (urticaria, angioedema, pruritus), respiratory (wheezing, coughing, laryngeal edema, rhinorrhea, watery/itching eyes),

gastrointestinal (vomiting, abdominal pain, diarrhea), and cardiovascular (if a systemic reaction occurs) systems.

An epitope is a binding site including an amino acid motif of between approximately six and fifteen amino acids which can be bound by either an immunoglobulin or recognized by a T cell receptor when presented by an antigen presenting cell in conjunction with the major histocompatibility complex (MHC). A linear epitope is one where the amino acids are recognized in the context of a simple linear sequence. A conformational epitope is one where the amino acids are recognized in the context of a particular three dimensional structure.

An immunodominant epitope is one which is bound by antibody in a large percentage of the sensitized population or where the titer of the antibody is high, relative to the percentage or titer of antibody reaction to other epitopes present in the same protein.

A decreased allergic reaction is characterized by a decrease in clinical symptoms following treatment of symptoms associated with exposure to an allergen, which can involve respiratory, gastrointestinal, skin, eyes, ears and mucosal surfaces in general.

An antigen presenting cell (an APC) is a cell which processes and presents peptides to T cells to elicit an antigen-specific response.

Immunostimulatory sequences are oligodeoxynucleotides of bacterial, viral or invertebrate origin that are taken-up by APCs and activate them to express certain membrane receptors (e.g., B7-1 and B7-2) and secrete various cytokines (e.g., IL-1, IL-6, IL-12, TNF). These oligodeoxynucleotides containing unmethylated CpG motifs cause brisk activation and when injected into animals in conjunction with antigen, appear to skew the immune response to a Th1-type response. See, for example, Yamamoto, et al., *Microbiol. Immunol.* 36, 983 (1992); Krieg, et al., *Nature* 374, 546-548 (1995); Pisetsky, *Immunity* 5, 303 (1996); and Zimmerman, et al., *J. Immunol.* 160, 3627-3630 (1998).

I. Diagnostic and Therapeutic Reagents.

The first step in making the modified allergen is to identify IgE binding sites and/or immunodominant IgE binding sites. The second step is to mutate one or more of the IgE binding sites, preferably including at a minimum one of the immunodominant sites, or to react the allergen with a compound that selectively blocks binding to one or more of the IgE binding sites. The third step is to make sufficient amounts of the modified allergen for administration to persons or animals in need of tolerance to the allergen, where the modified allergen is administered in a dosage and for a time to induce tolerance, or for diagnostic purposes. The modified allergen can be administered by injection, or in some cases, by ingestion or inhalation.

A. Allergens.

Many allergens are known that elicit allergic responses, which may range in severity from mildly irritating to life-threatening. Food allergies are mediated through the interaction of IgE to specific proteins contained within the food. Examples of common food allergens include proteins from peanuts, milk, grains such as wheat and barley, soybeans, eggs, fish, crustaceans, and mollusks. These account for greater than 90% of the food allergies (Taylor, Food Techn. 39, 146-152 (1992). The IgE binding epitopes from the major allergens of cow milk (Ball, et al. (1994) *Clin. Exp. Allergy*, 24, 758-764), egg (Cooke, S.K. and Sampson, H.R. (1997) *J. Immunol.*, 159, 2026-2032), codfish (Aas, K., and Elsayed, S. (1975) *Dev. Biol. Stand.* 29, 90-98), hazel nut (Elsayed, et al. (1989) *Int. Arch. Allergy Appl. Immunol.* 89, 410-415), peanut (Burks et al., (1997) *Eur. J. Biochemistry*, 245:334-339; Stanley et al., (1997) *Archives of Biochemistry and Biophysics*, 342:244-253), soybean (Herein, et al. (1990) *Int. Arch. Allergy Appl. Immunol.* 92, 193-198) and shrimp (Shanty, et al. (1993) *J. Immunol.* 151, 5354-5363) have all been elucidated, as have others. Other allergens include proteins from insects such as flea, tick, mite, fire ant, cockroach, and bee as well as molds, dust, grasses, trees, weeds, and proteins from mammals including horses, dogs, cats, etc.

The majority of allergens discussed above elicit a reaction when ingested, inhaled, or injected. Allergens can also elicit a reaction based solely on contact with the skin. Latex is a well known example. Latex products are manufactured from a milky fluid derived from the rubber tree, *Hevea brasiliensis* and other processing chemicals. A number of the proteins in latex can cause a range of allergic reactions. Many products contain latex, such as medical supplies and personal protective equipment. Three types of reactions can occur in persons sensitive to latex: irritant contact dermatitis, and immediate systemic hypersensitivity. Additionally, the proteins responsible for the allergic reactions can fasten to the powder of latex gloves. This powder can be inhaled, causing exposure through the lungs. Proteins found in latex that interact with IgE antibodies were characterized by two-dimensional electrophoresis. Protein fractions of 56, 45, 30, 20, 14, and less than 6.5 kd were detected (Posch A. et al., (1997) *J. Allergy Clin. Immunol.* 99(3), 385-395). Acidic proteins in the 8-14 kd and 22 - 24 kd range that reacted with IgE antibodies were also identified (Posch A. et al., (1997) *J. Allergy Clin. Immunol.* 99(3), 385-395. The proteins prohevein and hevein, from *hevea brasiliensis*, are known to be major latex allergens and to interact with IgE (Alenius, H., et al., *Clin. Exp. Allergy* 25(7), 659-665; Chen Z., et al., (1997) *J. Allergy Clin. Immunol.* 99(3), 402-409). Most of the IgE binding domains have been shown to be in the hevein domain rather than the domain specific for prohevein (Chen Z., et al., (1997) *J. Allergy Clin. Immunol.* 99(3), 402-409). The main IgE-binding epitope of prohevein is thought to be in the N-terminal, 43 amino acid fragment (Alenius H., et al., (1996) *J. Immunol.* 156(4), 1618-1625). The hevein lectin family of proteins has been shown to have homology with potato lectin and snake venom disintegrins (platelet aggregation inhibitors) (Kielisqewski, M.L., et al., (1994) *Plant J.* 5(6), 849-861).

B. Identification of IgE Binding Sites.

Allergens typically have both IgE and IgG binding sites and are recognized by T cells. The binding sites can be determined either by using

[illegible][illegible][illegible][illegible][illegible]

be preincubated with immobilized allergen. After washing to remove unbound Fab, the immobilized allergen would then be incubated with patient serum. After washing to remove unbound serum proteins, an incubation with a reporter-coupled secondary antibody specific for IgE Fc domain would be performed. Detection of bound reporter would allow quantitation of the extent to which serum IgE was prevented from binding to allergen by recombinant Fab. Maximal, uncompeteted serum IgE binding would be determined using allergen which had not been preincubated with Fab or had been incubated with nonsense Fab. If IgE binding persists in the face of competition from the complete set of allergen-specific IgE Fab clones, this experiment can be repeated using denatured antigen to determine whether the epitopes not represented among the cloned Fabs are linear or conformational.

Production of Recombinant or Modified Allergens

A modified allergen will typically be made using recombinant techniques. Expression in a procaryotic or eucaryotic host including bacteria, yeast, and baculovirus-insect cell systems are typically used to produce large (mg) quantities of the modified allergen. It is also possible to make the allergen synthetically, if the allergen is not too large, for example, less than about 25-40 amino acids in length.

Production of Transgenic Plants and Animals

Transgenic plants or animals expressing the modified allergens have two purposes. First, they can be used as a source of modified allergen for use in immunotherapy and second, appropriately modified plants or animals can be substituted for the original plant or animal, making immunotherapy unnecessary. Furthermore, it is possible that eating modified peanuts or cod fish, for example, could have either or both of two effects: (1) not imparting an allergic response on their own and (2) conferring protection from the unmodified source by acting as an immunotherapeutic agent for the unmodified source. Methods for engineering of plants and animals are well known and have been for a decade. For example, for plants see Day, (1996) *Crit. Rev. Food Sci. & Nut.* 36(S), 549-1014356

HS102cip2 11008/6

567, the teachings of which are incorporated herein. See also Fuchs and Astwood (1996) *Food Tech.* 83-88. Methods for making recombinant animals are also well established. See, for example, Colman, A" Production of therapeutic proteins in the milk of transgenic livestock" (1998) *Biochem. Soc. Symp.* 63, 141-147; Espanion and Niemann, (1996) *DTW Dtxch Tierarztl Wochenschr* 103(8-9), 320-328; and Colman, *Am. J. Clin. Nutr.* 63(4), 639S-6455S, the teachings of which are incorporated herein. One can also induce site specific changes using homologous recombination and/or triplex forming oligomers. See, for example, Rooney and Moore, (1995) *Proc. Natl. Acad. Sci. USA* 92, 2141-2149; Agrawal, et al., *BioWorld Today*, vol. 9, no. 41, p. 1"Chimeriplasty - Gene Surgery, Not Gene Therapy - Fixes Flawed Genomic Sequences" David N. Leff.

Production and Screening of Compounds blocking IgE Binding Sites

Once the IgE binding sites have been identified, it is also possible to block or limit binding to one or more of these sites by reacting the allergen with a compound that does not prevent the allergen from activating T cells, and in some embodiments does not significantly alter or decrease IgG binding capacity, resulting in a modified allergen similar in functionality to that produced by mutation. There are two principal ways to obtain compounds which block IgE binding sites: combinatorial libraries and combinatorial chemistry.

Identification of Compounds That Mask IgE Binding Sites through Application of Combinatorial Chemistry

In some cases it may be preferable to utilize non-peptide compounds to block binding of IgE to the allergen by masking the IgE binding epitope. This can be accomplished by using molecules that are selected from a complex mixture of random molecules in what has been referred to as "in vitro genetics" or combinatorial chemistry (Szostak, *TIBS* 19:89, 1992). In this approach a large pool of random and defined sequences is synthesized and then subjected to a selection and enrichment process. The selection and enrichment process involves the binding of the IgE binding epitopes to a solid support, followed by

interaction with the products of various combinatorial libraries. Those molecules which do not bind these molecules at all are removed immediately by elution with a suitable solvent. Those molecules which bind to the epitopes will remain bound to the solid support, whereas, unbound compounds will be removed from the column. Those compounds bound to the column can be removed, for example, by competitive binding. Following removal of these compounds, the compounds which have bound can be identified, using methodology well known to those of skill in the art, to isolate and characterize those compounds which bind to or interact with IgE binding epitopes. The relative binding affinities of these compounds can be compared and optimum compounds identified using competitive binding studies which are well known to those of skill in the art.

Identification of Compounds That Interact with IgE Binding Sites
through Application of Combinatorial Phage Display Libraries

Recombinant, monoclonal Fabs directed against conformational epitopes, identified as described above, can be used as reagents to assist in the definition of the biochemical nature of these epitopes. Cross-linking studies employing derivatized Fabs can be employed to label amino acid residues in the vicinity of the epitopes. Similarly, the Fabs can be used in protease protection studies to identify those domains of the allergen protein which are shielded from protease degradation by pre-binding of a specific Fab. Experiments employing recombinant monoclonal Fabs as reagents to label or protect from labeling should permit at least partial elucidation of the structures of conformational epitopes.

"Humanized" recombinant Fabs should bind to allergens if injected into a patient and thus prevent the binding of these allergens to native IgE. Since the Fabs cannot interact with the Fcε receptor, the binding of the IgE Fabs to allergen would not be expected to elicit mast cell degranulation. Allergen should be neutralized as it is by protective IgGs.

Anti-idiotypic antibodies directed against the conformational epitope-

In general, effective dosages will be in the picogram to milligram range, more typically microgram to milligram. Treatment will typically be between twice/weekly and once a month, continuing for up to three to five years, although this is highly dependent on the individual patient response.

The modified allergen can also be used as a diagnostic to characterize the patient's allergies, using techniques such as those described in the examples.

EXAMPLES

Peanut allergy is one of the most common and serious of the immediate hypersensitivity reactions to foods in terms of persistence and severity of reaction. Unlike the clinical symptoms of many other food allergies, the reactions to peanuts are rarely outgrown, therefore, most diagnosed children will have the disease for a lifetime (Sampson, H.A., and Burks, A.W. (1996) *Annu. Rev. Nutr.* 16, 161-77; Bock, S.A. (1985) *J. Pediatr.* 107, 676-680). The majority of cases of fatal food-induced anaphylaxis involve ingestion of peanuts (Sampson et al., (1992) *NEJM* 327, 380-384; Kaminogawa, S. (1996) *Biosci. Biotech. Biochem.* 60, 1749-1756). The only effective therapeutic option currently available for the prevention of a peanut hypersensitivity reaction is food avoidance. Unfortunately, for a ubiquitous food such as a peanut, the possibility of an inadvertent ingestion is great.

The examples described below demonstrate identification, modification, and assessment of allergenicity of the major peanut allergens, Ara h 1, Ara h 2, and Ara h 3. Detailed experimental procedures are included for Example 1. These same procedures were used for Examples 2-5. The nucleotide sequences of Ara h 1, Ara h 2, and Ara h 3, are shown in SEQ ID NOs. 1, 3, and 5, respectively. The amino acid sequences of Ara h 1, Ara h 2, and Ara h 3 are shown in SEQ ID NOs. 2, 4, and 6 respectively.

Example 1: Identification of linear IgE binding epitopes.

Due to the significance of the allergic reaction and the widening use of peanuts as protein extenders in processed foods, there is increasing interest in defining the allergenic proteins and exploring ways to decrease the risk to the

peanut-sensitive individual. Various studies over the last several years have identified the major allergens in peanuts as belonging to different families of seed storage proteins (Burks, et al. (1997) *Eur. J. Biochem.* 245, 334-339; Stanley, et al. (1997) *Arch. Biochem. Biophys.* 342, 244-253). The major peanut allergens Ara h 1, Ara h 2, and Ara h 3 belong to the vicilin, conglutin and glycinin families of seed storage proteins, respectively. These allergens are abundant proteins found in peanuts and are recognized by serum IgE from greater than 95% of peanut sensitive individuals, indicating that they are the major allergens involved in the clinical etiology of this disease (Burks, et al. (1995) *J. Clinical Invest.*, 96, 1715-1721). The genes encoding Ara h 1 (SEQ ID NO. 1), Ara h 2 (SEQ ID NO. 3), and Ara h 3 (SEQ ID NO. 5) and the proteins encoded by these genes (SEQ ID NO. 2, 4, 6) have been isolated and characterized. The following studies were conducted to identify the IgE epitopes of these allergens recognized by a population of peanut hypersensitive patients and a means for modifying their affinity for IgE.

Experimental Procedures

Serum IgE. Serum from 15 patients with documented peanut hypersensitivity reactions (mean age, 25 yrs) was used to determine relative binding affinities between wild type and mutant Ara h 1 synthesized epitopes. The patients had either a positive double-blind, placebo-controlled, food challenge or a convincing history of peanut anaphylaxis (laryngeal edema, severe wheezing, and/or hypotension; Burks, et al. (1988) *J. Pediatr.* 113, 447-451). At least 5 ml of venous blood was drawn from each patient, allowed to clot, and serum was collected. A serum pool from 12 to 15 patients was made by mixing equal aliquots of serum IgE from each patient. The pools were then used in immunoblot analysis.

Peptide synthesis. Individual peptides were synthesized on a derivatized cellulose membrane using 9-fluorenylmethoxycarbonyl (Fmoc) amino acid active esters according to the manufacturer's instructions (Genosys Biotechnologies, Woodlands, Texas; Fields, G.B. and Noble, R.L. (1990) *Int. J.*

software. A background area was scanned and subtracted from the obtained values. Following quantitation, wild type intensities were normalized to a value of one and the mutants were calculated as percentages relative to the wild type.

Synthesis and purification of recombinant Ara h 2 protein. cDNA encoding Ara h 2 was placed in the pET-24b expression vector. The pET-24 expression vector places a 6 x histidine tag at the carboxyl end of the inserted protein. The histidine tag allows the recombinant protein to be purified by affinity purification on a nickel column (HisBind resin). Recombinant Ara h 2 was expressed and purified according to the instructions of the pET system manual. Briefly, expression of the recombinant Ara h 2 was induced in 200 ml cultures of strain BL21(DE3) E. coli with 1 mM IPTG at mid log phase. Cultures were allowed to continue for an additional 3 hours at 36°C. Cells were harvested by centrifugation at 2000 x g for 15 minutes and then lysed in denaturing binding buffer (6 M urea, 5 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). Lysates were cleared by centrifugation at 39,000 x g for 20 minutes followed by filtration through 0.45 micron filters. The cleared lysate was applied to a 10 ml column of HisBind resin, washed with imidazole wash buffer (20 mM imidazole, 6 M urea, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). The recombinant Ara h 2 was then released from the column using elution buffer (1 M imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). The elution buffer was replaced with phosphate buffered saline by dialysis. The purification of recombinant Ara h 2 was followed by SDS PAGE and immunoblots. Peanut specific serum IgE was used as a primary antibody.

Skin prick tests. The ability of purified native and recombinant Ara h 2 to elicit the IgE mediated degranulation of mast cells was evaluated using prick skin tests in a peanut allergic individual. An individual meeting the criteria for peanut allergy (convincing history or positive double blind placebo controlled food challenge) and a non-allergic control were selected for the testing. Purified native and recombinant Ara h 2 and whole peanut extract (Greer Laboratories, Lenoir, N.C.) were tested. Twenty microliters of the test solution were applied to

the forearm of the volunteer and the skin beneath pricked with a sterile needle. Testing was started at the lowest concentration (less than or equal to 1 mg/ml) and increased ten fold each round to the highest concentration or until a positive reaction was observed. Mean diameters of the wheal and erythema were measured and compared to the negative saline control. A positive reaction was defined as a wheal 3mm larger than the negative control. Histamine was used as the positive control.

Results

Identification of the linear IgE-binding epitopes of Ara h 1, Ara h 2 and Ara h 3 allergens. Epitope mapping was performed on the Ara h 1, Ara h 2 and Ara h 3 allergens by synthesizing each of these proteins in 15 amino acid long overlapping peptides that were offset from each other by 8 amino acids. The peptides were then probed with a pool of serum IgE from 15 patients with documented peanut hypersensitivity. This analysis resulted in multiple IgE binding regions being identified for each allergen. The exact position of each IgE binding epitope was then determined by re-synthesizing these IgE reactive regions as 10 or 15 amino acid long peptides that were offset from each other by two amino acids. These peptides were probed with the same pool of serum IgE from peanut sensitive patients as used before. An example of this procedure for each of the peanut allergens is shown in Figures 1-3. Figure 1 shows amino acid residues 82-133 of Ara h 1, containing peptides 4, 5, 6, and 7, as identified in Table 1. Figure 2 shows amino acid residues 55-76 of Ara h 2, containing peptides 6 and 7, as shown in Table 2. Figure 3 shows amino acid residues 299-321 of Ara h 3, containing peptide 4 as identified in Table 3. This analysis revealed that there were 23 linear IgE binding epitopes on Ara h 1, 10 epitopes on Ara h 2, and 4 epitopes on Ara h 3.

In an effort to determine which, if any, of the epitopes were recognized by the majority of patients with peanut hypersensitivity, each set of epitopes identified for the peanut allergens were synthesized and then probed individually with serum IgE from 10 different patients. All of the patient sera tested

as determined by this analysis. All of these sequences can be found in SEQ ID NO 2.

Table 2. Ara h 2 IgE Binding Epitopes

EPITOPE	AA SEQUENCE	POSITION
1	<u>HASARQQWEL</u>	15-24
2	<u>QWELQD</u> RRRC	21-30
3	DRRC <u>QSQLER</u>	27-36
4	<u>LRPCEQHLMQ</u>	39-48
5	<u>KIQRDEDSYE</u>	49-58
6	YERDPYSPSQ	57-66
7	<u>SQDPYSPSPY</u>	65-74
8	DRLOGRQQEQ	115-124
9	<u>KRELRLNPQQ</u>	127-136
10	<u>QRCDLDVESG</u>	143-152

The underlined portions of each peptide are the smallest IgE binding sequences as determined by this analysis. All of these sequences can be found in SEQ ID NO 4.

Table 3. Ara h 3 IgE Binding Epitopes

EPITOPE	AA SEQUENCE	POSITION
1	<u>IETWNPNNQEFECAG</u>	33-47
2	<u>GNIFSGFTPEFLEQA</u>	240-254
3	<u>VTVRGGLRILSPDRK</u>	279-293
4	<u>DEDEYEYDEEDRRRG</u>	303-317

The underlined portions of each peptide are the smallest IgE binding sequences as determined by this analysis. All of these sequences can be found in SEQ ID NO 6.

Example 2 : Modification of peanut allergens to decrease allergenicity.

The major linear IgE binding epitopes of the peanut allergens were mapped using overlapping peptides synthesized on an activated cellulose membrane and pooled serum IgE from 15 peanut sensitive patients, as described in Example 1. The size of the epitopes ranged from six to fifteen amino acids in length. The amino acids essential to IgE binding in each of the epitopes were determined by synthesizing duplicate peptides with single amino acid changes at each position. These peptides were then probed with pooled serum IgE from 15 patients with peanut hypersensitivity to determine if the changes affected peanut-specific IgE binding. For example, epitope 9 in Table 1 was synthesized with an alanine or methionine residue substituted for one of the amino acids and probed. The following amino acids were substituted (first letter is the one-letter amino acid code for the residue normally at the position, the residue number, followed by the amino acid that was substituted for this residue; the numbers indicate the position of each residue in the Ara h 1 protein, SEQ ID NO. 2): Q143A, P144A; R145A; K146A; I147A; R148A; P149A; E150A; G151A; R152A; Q143M; P144M; R145M; K146M; I147M; R148M; P149M; E150M; G151M; R152M. The immunoblot strip containing the wild-type and mutated peptides of epitope 9 showed that binding of pooled serum IgE to individual peptides was dramatically reduced when either alanine or methionine was substituted for each of the amino acids at positions 144, 145, and 147-150 of Ara h 1 shown in SEQ ID NO. 2. Changes at positions 144, 145, 147, and 148 of Ara h 1 shown in SEQ ID NO. 2 had the most dramatic effect when methionine was substituted for the wild-type amino acid, resulting in less than 1% of peanut specific IgE binding to these peptides. In contrast, the substitution of an alanine for arginine at position 152 of Ara h 1 shown in SEQ ID NO. 2 resulted in increased IgE binding. The remaining Ara h 1 epitopes, and the Ara h 2 and Ara h 3 epitopes, were tested in the same manner and the intensity of IgE binding to each spot was determined as a percentage of IgE binding to the wild-type peptide. Any amino acid substitution that resulted in less than 1% of IgE

binding when compared to the wild type peptide was noted and is indicated in Tables 4-6. Table 4 shows the amino acids that were determined to be critical to IgE binding in each of the Ara h 1 epitopes. Table 5 shows the amino acids that were determined to be critical to IgE binding in each of the Ara h 2 epitopes. Table 6 shows the amino acids that were determined to be critical to IgE binding in each of the Ara h 3 epitopes.

This analysis indicated that each epitope could be mutated to a non-IgE binding-peptide by the substitution of a single amino acid residue.

The results discussed above for Ara h 1, Ara h 2, and Ara h 3 demonstrate that once an IgE binding site has been identified, it is possible to reduce IgE binding to this site by altering a single amino acid of the epitope. The observation that alteration of a single amino acid leads to the loss of IgE binding in a population of peanut-sensitive individuals is significant because it suggests that while each patient may display a polyclonal IgE reaction to a particular allergen, IgE from different patients that recognize the same epitope must interact with that epitope in a similar fashion. Besides finding that many epitopes contained more than one residue critical for IgE binding, it was also determined that more than one residue type (ala or met) could be substituted at certain positions in an epitope with similar results. This allows for the design of a hypoallergenic protein that would be effective at blunting allergic reactions for a population of peanut sensitive individuals. Furthermore, the creation of a plant producing a peanut where the IgE binding epitopes of the major allergens have been removed should prevent the development of peanut hypersensitivity in individuals genetically predisposed to this food allergy.

Table 4: Amino Acids Critical to IgE Binding of Ara h 1

EPITOPE	AA SEQUENCE	POSITION
1	AKSS <u>P</u> <u>Y</u> Q <u>K</u> KT	25-34
2	QEP <u>D</u> <u>D</u> LKQKA	48-57
3	LE <u>Y</u> <u>D</u> PRL <u>V</u> <u>Y</u> D	65-74
4	GE <u>R</u> TRGRQPG	89-98
5	PGDYDD <u>D</u> RRQ	97-106
6	PRREEGGRWG	107-116
7	REREED <u>W</u> RQ <u>P</u>	123-132
8	EDW <u>R</u> <u>R</u> <u>P</u> SHQQ	134-143
9	<u>Q</u> <u>P</u> <u>R</u> KIRPEGR	143-152
10	TPGQ <u>F</u> ED <u>F</u> FP	294-303
11	SYLQ <u>E</u> <u>F</u> SRNT	311-320
12	FNA <u>E</u> <u>F</u> NEIRR	325-334
13	EQEER <u>G</u> QRRW	344-353
14	DIT <u>N</u> <u>P</u> INLRE	393-402
15	NNFGK <u>L</u> FEVK	409-418
16	<u>R</u> <u>R</u> <u>Y</u> TARLKEG	498-507
17	EL <u>H</u> <u>L</u> <u>L</u> GFGIN	525-534
18	HRIFLAGD <u>K</u> D	539-548
19	IDQIEKQ <u>A</u> <u>K</u> D	551-560
20	KDLA <u>F</u> <u>P</u> <u>G</u> SGE	559-568
21	KESHFV <u>S</u> ARP	578-587

Note. The Ara h 1 IgE binding epitopes are indicated as the single letter amino acid code. The position of each peptide with respect to the Ara h 1 protein is indicated in the right hand column. The amino acids that, when altered, lead to loss of IgE binding are shown as the bold, underlined residues. Epitopes 16 and 23 were not included in this study because they were recognized by a single patient who was no longer available to the study. All of these sequences can be found in SEQ ID NO 2.

As shown by Figure 4, hydrophobic amino acids are more critical to IgE binding. The type of each amino acid within the Ara h 1 epitopes was assessed relative to its importance to IgE binding. The closed boxes represent the total number of a particular type of amino acid residue found in all of the Ara h 1 epitopes, whereas the open boxes represent the number of that type of residue

which, when replaced, was found to result in the loss of IgE binding.

The tertiary structure of Ara h 1 consists of two sets of opposing anti-parallel beta-sheets in swiss roll topology joined by an inter-domain linker. The terminal regions of the molecule consist of alpha-helical bundles containing three helices each. Epitope 12 resides on an N-terminal alpha-helix while epitopes 20 and 21 are located on C-terminal alpha-helices. Epitopes 14, 15, and 18 are primarily beta-strands on the inner faces of the domain and epitopes 16, 17, 19, and 22 are beta-strands on the outer surface of the domain. The remainder of the epitopes are without a predominant type of higher secondary structure. Of the 35 residues that affected IgE binding, 10 were buried beneath the surface of the molecule, and 25 were exposed on the surface.

Table 5. Amino Acids Critical to IgE Binding of Ara h 2

	EPITOPE	AA SEQUENCE	POSITION
	1	HASAR Q <u>Q</u> WEL	15-24
15	2	<u>Q</u> WEL Q GDRRC	21-30
	3	D RRC Q S Q LER	27-36
	4	L R P CE Q HLMQ	39-48
	5	K I Q R D E D SYE	49-58
	6	YER D <u>P</u> YSPSQ	57-66
20	7	S Q <u>D</u> PYSPSPY	65-74
	8	DR L <u>Q</u> G R Q QEQ	115-124
	9	K REL R N L PQQ	127-136
	10	QRC D <u>L</u> D <u>V</u> ESG	143-152

Note. The Ara h 2 IgE binding epitopes are indicated as the single letter amino acid code. The position of each peptide with respect to the Ara h 2 protein is indicated in the right hand column. The amino acids that, when altered, lead to loss of IgE binding are shown as the bold, underlined residues. All of these sequences can be found in SEQ ID NO 4.

Table 6. Amino Acids Critical to IgE-Binding of Ara h 3.

	EPITOPE	AA SEQUENCE	POSITION
	1	IETWNPNNQEFECAG	33-47
	2	GNI <u>F</u> SG <u>F</u> TPE <u>F</u> LEQA	240-254
5	3	VTVRGGLRILSPDRK	279-293
	4	DEDEYEYDEEDRRRG	303-317

Note. The Ara h 3 IgE binding epitopes are indicated as the single letter amino acid code. The position of each peptide with respect to the Ara h 3 protein is indicated in the right hand column. The amino acids that, when altered, lead to loss of IgE binding are shown as the bold, underlined. All of these sequences can be found in SEQ ID NO 6.

IgE-binding peptides 1-4 were synthesized and probed individually with serum igE from 20 peanut-hypersensitive patients. The percentage of individual peanut-hypersensitive patients recognizing epitopes 1-4 ranges from 5% to 100%. The IgE-binding sequence and its corresponding position in the primary sequence of Ara h 3 is also shown in Table 7.

Table 7. Percentage of recognition of Ara 3 Peptides

	Sequence	Position	Precentage
	EQEFLRYQQQ	183-192	5% (1/2)
20	FTPEFLEQAF	246-255	25% (5/20)
	EYEYDEEDRR	300-309	35% (7/20)
	LYRNALFVAH	379-388	100% (20/20)

Example 3: A Modified Ara h 2 Protein Binds less IgE But Similar Amounts of IgG.

In order to determine the effect of changes to multiple epitopes within the context of the intact allergen, four epitopes (including the three immunodominant epitopes) of the Ara h 2 allergen were mutagenized and the protein produced recombinantly. The amino acids at position 20, 31, 60, and 67 of the Ara h 2 protein (shown in SEQ ID NO. 4) were changed to alanine by mutagenizing the gene encoding this protein by standard techniques. These

residues are located in epitopes 1, 3, 6, and 7 and represent amino acids critical to IgE binding that were determined in Example 2. The modified and wild-type versions of this protein were produced and immunoblot analysis performed using serum from peanut sensitive patients. These results showed that the modified version of this allergen bound significantly less IgE than the wild type version of these recombinant proteins (Figure 5) but bound similar amounts of IgG.

Example 4: Binding of IgE to Modified Ara h 3 peptides.

Peptide 2 was synthesized with an alanine residue (except position 254) which was substituted with leucine) substituted for one of the amino acids at each position in the peptide. The synthesized peptides were probed with a pool of serum IgE from peanut hypersensitive patients whose IgE has previously been shown to recognize this peptide.

The results show binding with T A, 247; P A, 248; E A, 249; E A, 252, Q A, 253, and wild-type. Very little binding was detectable with f A, 246, F A, 250, L A, 251, A L, 254, and F A, 255.

Example 5: A modified Ara h 2 protein retains the ability to stimulate T-cells to proliferate.

The modified recombinant Ara h 2 protein described in Example 3 was used in T-cell proliferation assays to determine if it retained the ability to activate T cells from peanut sensitive individuals. Proliferation assays were performed on T-cell lines grown in short-term culture developed from six peanut sensitive patients. T-cells lines were stimulated with either 50 µg of crude peanut extract, 10 µg of native Ara h 2, 10 µg of recombinant wild-type Ara h2, or 10 µg of modified recombinant Ara h 2 protein and the amount of 3H-thymidine determined for each cell line. Results were expressed as the average stimulation index (SI) which reflected the fold increase in 3H-thymidine incorporation exhibited by cells challenged with allergen when compared with media treated controls (Figure 6).

Ara h 2 T cell-binding epitopes include amino acids 18-28, 45-55, 95-1014356

HS102cip2 11008/6

108, and 134-144.

Example 6: Identification of T-Cell Epitopes on Ara h 2.

The development of an IgE response to an allergen involves a series of interactions between antigen-presenting cells (APCs), T cells, and B cells.

5 Overlapping synthetic peptides spanning the entire protein were used to determine the T cell epitopes of Ara h 2. Peanut specific T cell lines were established from the peripheral blood of 12 atopic patients and 4 nonatopic controls. All of the cell lines were shown to consist of predominantly CD4⁺ T cells. The proliferation of the T cells in response to the 29 individual peptides
10 was measured. Four immunodominant T cell epitopes were identified for Ara h 2, epitope 1 (AA 18-28), epitope 2 (AA 45-55), epitope 3 (AA 95-108), and epitope 4 (134-144). Epitopes 1, 2, and 4 have overlapping sequences with Ara h 2 B cell epitopes whereas epitope 3 does not overlap IgE binding epitopes, providing the possibility for the development of a non-anaphylactic, T cell
15 directed, immunotherapeutic peptide.

This process was repeated with T cells isolated from 17 peanut allergic individuals and 5 non-peanut allergic individuals, placed in to 96 well plates at 4 x 10⁴ cells/well and treated in triplicates with media or Ara h 2 peptides (10 micrograms/ml). The cells were allowed to proliferate for 6 days and then
20 incubated with ³H-thymidine (1 microCi/well) at 37 C for 6-8 hrs and then harvested onto glass fiber filters. T cell proliferation was estimated by quantitating the amount of ³H-thymidine incorporation into the DNA of proliferation cells. ³H-thymidine incorporation is reported as stimulation (SI) above media treated control cells. Graphs of the proliferation of T cells (x-axis)
25 from each individual plotted versus the 29 overlapping peptides (y-axis) spanning the entire Ara h 2 protein from the amino to carboxyl terminus (peptide 932) were prepared.

T cells were stained with FITC-labeled anti-CD4 and FITC-labeled anti-CD8 antibodies in order to determine the phenotype of the peanut specific T-cell
30 lines established. FACS analysis was used to determine the percent of CD4+

and CD8+ cells in the peanut specific T-cell lines utilized in Ara h 2 epitope mapping and plotted versus the initials of the individual patients used to establish these cell lines. The supernatant was collected from T-cells stimulated with immunodominant peptides and an ELISA assay was utilized to measure IL-4 concentrations in the media. IL-4 concentration was plotted versus the 29 overlapping peptides spanning the entire Ara h2 protein from amino to carboxyl terminus.

Four immunodominant T cell epitopes were initially identified for ara h 2: peptides 907-908 (epitope 1), 911-914 (epitope 2), 923-926 (epitope 3), and 930-932 (epitope 4). Similar T cell epitopes were identified for Ara h 2 using T cells isolated from 5 non-atopic individuals as well as cells isolated from 17 atopic individuals. T cell lines from both atopic and non-atopic individuals were primarily CD4+. T cells from both atopic and non-atopic individuals seemed to secrete more IL-4 in response to epitope 2 than epitope 1. On average, T cells of 15 th non-atopic individuals secreted lower levels of IL4 than the T cells of atopic individuals.

Table 8 is a list of ara h 2 B- cell and T-cell epitopes.

Table 8: Ara h 2 B-cell and T-cell Epitopes.

<u>B-cell Epitope Number</u>	<u>Amino Acid Sequence</u>	<u>Ara h 2 Position</u>
3	DRRCQSQLER	27-36
6	YERDPYSPSQ	57-66
7	SQDPYSPSPY	65-74
<u>T-cell Epitope Number</u>	<u>Amino Acid Sequence</u>	<u>Ara h 2 Position</u>
1	RQQWELQGDRRCQSQ	19-33
2	LRPCEQHLMQKIQRDEDSYE	39-58
3	HQERCCNELN	84-93
4	QRCMCEALQQ	99-109
5	PQQCGLRAPQ	135-148

When comparing the B cell and T cell epitopes it is evident that the immunodominant epitopes do not overlap to any significant extent. This is very

important in the development of peptide mediated immunotherapies towards modulating Th cell development to favor Th1 type cytokine responses.

Example 7: A Modified Ara h 2 Protein Elicits a Smaller Wheal and Flare in Skin Prick Tests of a Peanut Sensitive Individual.

5 The modified recombinant Ara h 2 protein described in Example 3 and the wild type version of this recombinant protein were used in a skin prick test of a peanut sensitive individual. Ten micrograms of these proteins were applied separately to the forearm of a peanut sensitive individual, the skin pricked with a sterile needle, and 10 minutes later any wheal and flare that developed was
10 measured. The wheal and flare produced by the wild-type Ara h 2 protein (8 mm X 7 mm) was approximately twice as large as that produced by the modified Ara h 2 protein (4 mm X 3mm). A control subject (no peanut hypersensitivity) tested with the same proteins had no visible wheal and flare but, as expected, gave positive results when challenged with histamine. In addition, the test
15 subject gave no positive results when tested with PBS alone. These results indicate that an allergen with only 40% of its IgE binding epitopes modified (4/10) can give measurable reduction in reactivity in an *in vivo* test of a peanut sensitive patient.

These same techniques can be used with the other known peanut
20 allergens, Ara h 1 (SEQ ID NO 1 and 2), Ara h 3 (SEQ ID NO. 5 and 6), or any other allergen.

Example 8: IgE binding sites may be blocked by or formed in part by carbohydrate structures.

25 Studies demonstrated that the Ara h 1 trimer, which is stable at high salt concentration, is unstable at an acidic pH (2.1) that is found in the human stomach. The allergen was digested with pepsin, trypsin, and chymotrypsin.

Purified Ara h 1 (9.5 microM) was subjected to digestion with trypsin (0.01 microM) at 37C for varying lengths of time up to three hours. Samples were withdrawn at various times and prepared for analysis.

30 Portions were resistant to digestion. These peptides contain IgE binding

epitopes, as demonstrated by immunoblot analysis using a pool of serum IgE from peanut sensitive patients. Immunoblot analysis with an antibody that recognizes a unique carbohydrate structure that includes a beta-1,2-linked xylose attached to the beta-linked mannose of the core oligosaccharide chain showed protease resistant fragments in all samples for up to three hours after addition of the enzyme, many of which were glycosylated. Most peptides of the protease-resistant Ara h 1 peptides contain a beta-1,2-linked xylose attached to the beta-linked mannose of the core oligosaccharide chain.

We claim:

1. A method of making a modified allergen which is less reactive with IgE comprising
 - (a) identifying IgE binding sites in an allergen;
 - (b) modifying the allergen by mutating at least one amino acid in an IgE binding site or reacting the allergen with a compound blocking binding to at least one amino acid in an IgE binding site;
 - (c) screening for IgE binding to the modified allergen using serum or antibodies from a pooled patient population and screening for activation of T cells; and
 - (d) selecting the modified allergens which have decreased binding to IgE as compared to the unmodified allergen and which activate T cells.
2. The method of claim 1 further comprising screening for binding of the modified allergen for binding to IgG and selecting the modified allergens which have decreased binding to IgE, activate T cells and bind to IgG.
3. The method of claim 1 wherein the modified allergen is mutated in the center of one or more of the IgE binding sites.
4. The method of claim 1 wherein the modified allergen is mutated by substituting a hydrophobic amino acid in the center of one or more of the IgE binding sites with a neutral or hydrophilic amino acid.
5. The method of claim 1 wherein binding of IgE to the modified allergen is blocked by reaction of a compound with at least one amino acid present in an IgE binding site.
6. The method of claim 5 wherein binding of IgE is blocked by reaction of the allergen with an antibody which blocks binding to one or more IgE sites but allows the allergen to still activate T cells.
7. The method of claim 1 wherein the modified allergen is a portion of a protein.

8. The method of claim 1 wherein the modified allergen is formulated with an adjuvant selected from the group consisting of IL 12, IL 16, IL 18, Ifn- γ or immune stimulatory sequences.
9. The method of claim 1 wherein the modified allergen is screened for initiation of a T cell helper 1 response.
10. The method of claim 1 wherein the modified allergen is made in a recombinant host selected from the group consisting of plants, animals, bacteria, yeast, fungi, and insect cells.
11. The method of claim 1 wherein the modified allergen is made in cells using site specific mutation.
12. The method of claim 1 wherein the modified allergen is made from a peanut allergen selected from the group consisting of Ara h 1, Ara h 2, and Ara h 3.
13. The method of claim 1 wherein the modified allergen is based on a protein obtained from a source selected from the group consisting of legumes, milks, grains, eggs, fish, crustaceans, mollusks, insects, molds, dust, grasses, trees, weeds, mammals, birds, and natural latexes.
14. A modified allergen which is less reactive with IgE comprising at least one IgE binding site present in the allergen modified by at least one amino acid change or having at least one amino acid bound by a compound so that the site no longer binds IgE, wherein the modified allergen activates T cells.
15. The modified allergen of claim 14 wherein the modified allergen binds IgG.
16. The modified allergen of claim 14 made by the process of
 - (a) identifying one or more IgE binding sites in an allergen;
 - (b) mutating at least one amino acid in an IgE binding site;
 - (c) screening for IgE binding to the mutated allergen and activation of T cells by the mutated allergen; and
 - (d) selecting the modified allergens with decreased binding to IgE which activate T cells.

17. The modified allergen of claim 14 wherein the modified allergen is mutated in the center of one or more of the IgE binding sites.
18. The modified allergen of claim 14 wherein the modified allergen is mutated by substituting a hydrophobic amino acid in the center of one or more of the IgE binding sites with a neutral or hydrophilic amino acid.
19. The modified allergen of claim 14 wherein binding of IgE is blocked by reaction of a compound with at least one amino acid present in an IgE binding site.
20. The modified allergen of claim 19 wherein binding of IgE is blocked by reaction of the allergen with an antibody which blocks binding to one or more IgE sites but allows the allergen to still activate T cells.
21. The modified allergen of Claim 20 wherein the modified allergen does not have significantly altered or decreased IgG binding capacity.
22. The modified allergen of claim 14 which initiates a T cell helper 1 response.
23. The modified allergen of claim 14 wherein the allergen is a portion of a protein.
24. The modified allergen of claim 14 wherein the modified allergen is formulated with an adjuvant selected from the group consisting of IL 12, IL 16, IL 18, Ifn- γ and immune stimulatory sequences.
25. The modified allergen of claim 14 wherein the modified allergen is made in a transgenic plant or animal.
26. The modified allergen of claim 14 expressed in a recombinant host selected from the group consisting of plants and animals.
27. The modified allergen of claim 17 expressed in a recombinant host selected from the group consisting of bacteria, yeast, fungi, and insect cells.
28. The modified allergen of claim 14 wherein the modified allergen is based on a protein obtained from a source selected from the group consisting of legumes, milks, grains, eggs, fish, crustaceans, mollusks, insects, molds, dust, grasses, trees, weeds, mammals, birds, and natural latexes.

29. The modified allergen of claim 14 wherein the modified allergen is made from a peanut allergen selected from the group consisting of Ara h 1, Ara h 2, and Ara h 3.

30. A nucleotide molecule encoding a modified allergen which is less reactive with IgE comprising at least one IgE binding site present in the allergen modified by at least one amino acid change so that the site no longer binds IgE, but wherein the modified allergen activates T cells.

31. The molecule of claim 30 in a vector for expression in a recombinant host.

32. A nucleotide molecule for causing a site specific mutation in a gene encoding a protein which yields a modified allergen which is less reactive with IgE comprising at least one IgE binding site present in the allergen modified by at least one amino acid change so that the site no longer binds IgE, but wherein the modified allergen activates T cells.

33. A transgenic plant expressing a modified allergen which is less reactive with IgE comprising at least one IgE binding site present in the allergen modified by at least one amino acid change so that the site no longer binds IgE, but wherein the modified allergen activates T cells.

34. A transgenic animal expressing a modified allergen which is less reactive with IgE comprising at least one IgE binding site present in the allergen modified by at least one amino acid change so that the site no longer binds IgE, but wherein the modified allergen activates T cells.

35. A compound selectively binding to at least one amino acid in an IgE binding site of an allergen, wherein the site no longer binds IgE, but wherein the allergen is able to activate T cells, wherein the compound is obtained using a combinatorial library or combinatorial chemistry and screening for reaction with the allergen to produce bound allergen, followed by testing of the bound allergen for binding to IgE and activation of T cells.

36. A method to treat an individual to reduce the clinical response to an allergen comprising administering to the individual a modified allergen which is

less reactive with IgE comprising at least one IgE binding site present in the allergen modified by at least one amino acid change or having at least one amino acid bound by a compound so that the site no longer binds IgE, wherein the modified allergen activates T cells, in an amount and for a time sufficient to reduce the allergic reaction to the unmodified allergen.

008610" 96045450

METHODS AND REAGENTS FOR DECREASING CLINICAL REACTION TO ALLERGY

Abstract

It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

008210-96046450




FIGURE 4




FIG. 6




FIG. 1




FIG. 2




FIG. 3




FIG. 5

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below), or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHODS AND REAGENTS FOR DECREASING CLINICAL REACTION TO ALLERGY

the specification of which (check one)

___ is attached hereto

X was filed on January 28, 2000

as application Serial No. _____

___ and was amended on: _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Claimed
<u>PCT/US99/02031</u> (Number)	<u>PCT</u> (Country)	<u>29/01/1999</u> (Day/Month/Year Filed)	<u>Yes</u>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	_____
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	_____

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number

Filing Date

60/074,590
(Number)

February 13, 1998
(Day/Month/Year Filed)

60/074,624
(Number)

February 13, 1998
(Day/Month/Year Filed)

60/074,633
(Number)

February 13, 1998
(Day/Month/Year Filed)

60/073,283
(Number)

January 31, 1998
(Day/Month/Year Filed)

(via 09/240,557, filed January 29, 1999
09/241,101, filed January 29, 1999
09/248,673, filed February 11, 1999)

60/122,566
(Number)

March 2, 1999

U.S.S.N.:
Filed: January 28, 2000
DECLARATION
"METHODS AND REAGENTS FOR DECREASING CLINICAL REACTIONS TO ALLERGY

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>09/141,220</u> (Application Serial No.)	<u>August 27, 1998</u> (Filing Date)	<u>Pending</u> Status (patented, pending, abandoned)
<u>09/240,557</u> (Application Serial No.)	<u>January 29, 1999</u> (Filing Date)	<u>Pending</u> Status (patented, pending, abandoned)
<u>09/241,101</u> (Application Serial No.)	<u>January 29, 1999</u> (Filing Date)	<u>Pending</u> Status (patented, pending, abandoned)
<u>09/248,673</u> (Application Serial No.)	<u>February 11, 1999</u> (Filing Date)	<u>Pending</u> Status (patented, pending, abandoned)
<u>09/267,719</u> (Application Serial No.)	<u>March 11, 1999</u> (Filing Date)	<u>Pending</u> Status
<u>09/248,674</u> (Application Serial No.)	<u>February 11, 1999</u> (Filing Date)	<u>Pending</u> Status (patented, pending, abandoned)

As named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Patrea L. Pabst	31,284
Robert A. Hodges	41,074
Kevin W. King	42,737

Send Correspondence to: Patrea L. Pabst, Esq.
ARNALL GOLDEN & GREGORY LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, GA 30309-3450

Direct telephone calls to: Patrea L. Pabst (404) 873-8794

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such

U.S.S.N.:

Filed: January 28, 2000

DECLARATION

-METHODS AND REAGENTS FOR DECREASING CLINICAL REACTIONS TO ALLERGY

willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Gary A. Bannon _____ Date _____
Inventor's signature _____

Residence 714 St. Michael Place, Little Rock, Arkansas 72211 _____

Citizenship United States of America. _____

Post Office Address 714 St. Michael Place, Little Rock, Arkansas 72211 _____

Full name of second inventor A. Wesley Burks Jr. _____

Inventor's signature _____ Date _____

Residence 2400 North Pierce, Little Rock, Arkansas 72207 _____

Citizenship United States of America _____

Post Office Address 2400 North Pierce, Little Rock, Arkansas 72207 _____

Full name of third inventor Hugh A. Sampson _____

Inventor's signature _____ Date _____

Residence 19 Carleon Avenue, Larchmont, New York 10538 _____

Citizenship United States of America _____

Post Office Address 19 Carleon Avenue, Larchmont, New York 10538 _____

Full name of fourth inventor Howard B. Sosin _____


Inventor's signature _____ Date _____

Residence 640 Sasco Hill Road, Fairfield, Connecticut 06430 _____

Citizenship United States of America. _____

Post Office Address 640 Sasco Hill Road, Fairfield, Connecticut 06430 _____

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☒ Page(s) 22 of Specification were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available.

PRINT OF DRAWINGS
AS ORIGINALLY FILED